<--- Back to Details
First PageDocument Content
Breast cancer / Alkaloids / Benzoates / Protein-bound paclitaxel / Paclitaxel / Abraxis BioScience / Metastatic breast cancer / Adjuvant therapy / Food and Drug Administration / Chemistry / Medicine / Organic chemistry
Breast cancer
Alkaloids
Benzoates
Protein-bound paclitaxel
Paclitaxel
Abraxis BioScience
Metastatic breast cancer
Adjuvant therapy
Food and Drug Administration
Chemistry
Medicine
Organic chemistry

NDA[removed]Abraxane Letter

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 62,46 KB

Share Document on Facebook

Similar Documents

Bioluminescent orthotopic PDX models of primary pancreatic cancer and residual/metastatic breast cancer to predict efficacy of standard of care and experimental treatments Benjamin G. 1 Cuiffo ,

Bioluminescent orthotopic PDX models of primary pancreatic cancer and residual/metastatic breast cancer to predict efficacy of standard of care and experimental treatments Benjamin G. 1 Cuiffo ,

DocID: 1uQqF - View Document

Jose Falcon Father, Co-Survivor and Veteran Tour de Pink Rider My name is Jose Falcon and I am the proud father and caregiver to my only daughter, Kayla Falcon. She was diagnosed with Stage 4 Metastatic breast cancer at

Jose Falcon Father, Co-Survivor and Veteran Tour de Pink Rider My name is Jose Falcon and I am the proud father and caregiver to my only daughter, Kayla Falcon. She was diagnosed with Stage 4 Metastatic breast cancer at

DocID: 1trwM - View Document

· METASTATIC BREAST CANCER ·  Assessing Treatment Response in Metastatic Breast Cancer Shlomit Strulov Shachar, MD, and Hyman B. Muss, MD  Abstract

· METASTATIC BREAST CANCER · Assessing Treatment Response in Metastatic Breast Cancer Shlomit Strulov Shachar, MD, and Hyman B. Muss, MD Abstract

DocID: 1rmV3 - View Document

Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer

Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer

DocID: 1riiF - View Document

Media release, October 23, 2014  Stopping anti-CCL2 breast cancer treatment aggravates the disease Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scienti

Media release, October 23, 2014 Stopping anti-CCL2 breast cancer treatment aggravates the disease Mohamed Bentires-Alj and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) together with scienti

DocID: 1rf3r - View Document